COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 2 FDA records to the applicant name Baxter Healthcare Corporation. It includes 1 original PMA approval. 1 entry is a PMA supplement. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from May 19, 2023 to Nov 7, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code LMG appears in 2 of the 2 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P210036, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 25212 W. Illinois Rte. 120, Round Lake, IL, 60073. Recorded on P210036/S010, decision dated Nov 7, 2026.
Device categories in this collection
Agent, Absorbable Hemostatic, Non-Collagen Based.
Changes described in PMA records
The FDA recorded an approval decision on 2026-11-07 for P210036/S010, a supplement to PerClot Absorbable Hemostatic Powder Accessory Tips held by Baxter Healthcare Corporation. The supplement was filed under the Normal 180 Day Track No User Fee category, with the recorded reason being a location change affecting a manufacturer, sterilizer, packager or supplier. The decision statement describes approval for a new manufacturing site.
This action covers a site change within the existing application rather than a new approval of the device itself. The product is listed under the non-collagen based absorbable hemostatic agent category, product code LMG, with specialties recorded as general and plastic surgery. The source record does not identify the specific facility, the manufacturing step affected, or any supporting documents, so the scope of the site change and any review basis remain unknown.
FDA approval-order wording
approval for a new manufacturing site
Nov 7, 2026 · Normal 180 Day Track No User FeeFDA lists this as approval of the PerClot® Absorbable Hemostatic Powder, not a broader change to the whole PerClot® Polysaccharide Hemostatic System. The cited scope is surgical procedures, excluding neurological and ophthalmic use, as an adjunctive hemostatic device for suture line bleeding or capillary, venous and arteriolar bleeding.
The statement gives the intended use only; it does not provide a new indication, trial detail, or evidence summary in this record. It also does not say whether this was a first PMA or a supplement, so the relationship to an earlier PMA cannot be resolved from the supplied fields alone.
FDA approval-order wording
Approval for the PerClot Absorbable Hemostatic Powder. The device is indicated in surgical procedures (except neurological and ophthalmic) as an adjunctive hemostatic device to assist when control of suture line bleeding or capillary, venous and arteriolar bleeding by pressure, ligature, and other conventional procedures is ineffective or impractical.
May 19, 2023Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.